Bone Biologics Corp. operates as a medical device company. The company is headquartered in Burlington, Massachusetts and currently employs 2 full-time employees. The company went IPO on 2015-11-27. The firm is focused on bone regeneration in lumbar spinal fusion using neural epidermal growth factor-like 1 protein (NELL-1) in combination with demineralized bone matrix (DBM), a demineralized bone matrix from the Musculoskeletal Transplant Foundation (MTF) Biologics. The combination NELL-1/DBM medical device is an osteopromotive recombinant protein that provides target specific control over bone regeneration. NELL-1 in combination with DBM. NELL-1, a proprietary skeletal-specific growth factor that is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.
Follow-Up Questions
BBLG hissesinin fiyat performansı nasıl?
BBLG 'in mevcut fiyatı $2.49 'dir, son işlem günde 0.62% increased etti.
Bone Biologics Corp için ana iş temaları veya sektörler nelerdir?
Bone Biologics Corp Biotechnology endüstrisine ait ve sektör Health Care 'dir
Bone Biologics Corp 'in piyasa değerlemesi nedir?
Bone Biologics Corp 'in mevcut piyasa değerlemesi $4.4M 'dir
Bone Biologics Corp al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 3 analist Bone Biologics Corp için analist derecelendirmeleri gerçekleştirdi, bunlar 2 güçlü al, 4 al, 1 tut, 0 sat ve 2 güçlü sat içermektedir
